April 4, 2022
InSysBio announces its participation in Quantitative Systems Pharmacology for Immuno-Oncology, a joint meeting of the EMBL's European Bioinformatics Institute (EMBL-EBI) & the UK QSP Network which is to be held 25th & 26th April 2022 in person at the EMBL-EBI Main Building, Wellcome Genome Campus, Hinxton, Cambridgeshire, UK, and online via Zoom.
Oleg Demin Jr, InSysBio Scientific & Marketing Director, Oncology & Immuno-Oncology, will give a talk in frames of Theme 1: Combination Therapy.
Monday, April 25, 11:20-11:45
About InSysBio
InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.
| ← | October 2024 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
|
3
|
4
1.
04 Oct 2024 16:13
InSysBio to participate in SITC 2024
InSysBio announces its participation in SITC’s 39th Annual Meeting which is to be held from November 6-10, 2024, at George R. Brown Convention Center in Houston, TX, USA. InSysBio team is going to present its Mechanistic modeling services and tools to support development of immunotherapies at Booth #1032 and 3 posters in frames of the Meeting
|
5
|
6
| |
|
7
|
8
|
9
|
10
|
11
|
12
|
13
|
|
14
|
15
|
16
1.
16 Oct 2024 19:36
InSysBio to take part in "An Introduction to QSP" event
InSysBio announces its participation in An Introduction to QSP, A UK QSP Network hybrid (in person/online) event which is to be held 17-20hrs 24th October 2024. Oleg Demin Jr, Scientific Director, Oncology & Immuno-Oncology, will discuss the prediction of the first-in-human dose for T-cell engagers using mechanistic modelling
|
17
|
18
|
19
|
20
|
|
21
|
22
|
23
|
24
|
25
|
26
|
27
|
|
28
|
29
|
30
|
31
| |||
Thank you for your message! We will get back to you shortly.
